BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5551 related articles for article (PubMed ID: 471128)

  • 1. Histologic changes in the human skin melanoma after intratumorous treatment with BCG.
    Svejda J; Mechl Z; Sopková B; Foukal T
    Neoplasma; 1979; 26(2):215-21. PubMed ID: 471128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multiple BCG-induced ulcers after subcutaneous vaccination in the framework of immunochemotherapy in malignant melanoma].
    Korting HC; Strasser S; Konz B
    Hautarzt; 1988 Mar; 39(3):170-3. PubMed ID: 3378889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
    Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
    Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
    MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
    Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in malignant melanomaa.
    Homes EC; Morton DL; Eilber FR; Golub SE; Sulit HL
    Natl Cancer Inst Monogr; 1976 Nov; 44():85-6. PubMed ID: 799763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
    Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
    Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [BCG-treatment of malignant melanoma].
    Borberg H
    Internist (Berl); 1975 Oct; 16(10):482-5. PubMed ID: 1107254
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule.
    Gutterman JU; Mavligit G; McBride C; Frei E; Hersh EM
    Natl Cancer Inst Monogr; 1973 Dec; 39():205-12. PubMed ID: 4595319
    [No Abstract]   [Full Text] [Related]  

  • 9. [Immunotherapy of malignant melanomas].
    Macher E
    Haematol Blood Transfus; 1978; 21():285-91. PubMed ID: 738638
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of the complications occurring in BCG vaccine immunotherapy of patients with malignant neoplasms].
    Grigorovich NA; Risina DIa; Nodel'son SE
    Vopr Onkol; 1984; 30(7):102-6. PubMed ID: 6464396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of melanoma with intralesional BCG.
    Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
    Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
    [No Abstract]   [Full Text] [Related]  

  • 12. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
    Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
    Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intrafocal BCG therapy of metastasizing malignant melanoma].
    Kunze J; Lesch R; Plagwitz R; Hagedorn M
    Hautarzt; 1978 Nov; 29(11):597-600. PubMed ID: 721465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R; Wybran J; Epstein W
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunoreactivity in patients with surgically removed melanoma in the course of BCG vaccination (author's transl)].
    Lochman I; Kyselá T; Machálek J; Lochmanová A; Beska F
    Cesk Dermatol; 1980; 55(6):372-7. PubMed ID: 7460040
    [No Abstract]   [Full Text] [Related]  

  • 17. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro assay of cell-mediated immunity in BCG therapy of malignant melanoma: a preliminary report.
    Nathanson L; Clark DA
    Natl Cancer Inst Monogr; 1973 Dec; 39():221-4. PubMed ID: 4595321
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunological changes in cancer patients receiving BCG.
    Cochran AJ; Mackie RM; Jackson AM; Ogg LJ; Ross CE
    Dev Biol Stand; 1977 Apr 13-15; 38():441-8. PubMed ID: 608535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cell-mediated BCG-diagnosis using a multipuncture apparatus in melanoma].
    Wolf M
    Dermatol Monatsschr; 1976 Sep; 162(9):756-7. PubMed ID: 992184
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 278.